April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Mesenchymal Stem Cell Transplantation Confers Neuroprotection in Experimental Glaucoma
Author Affiliations & Notes
  • T. V. Johnson
    SMMG, LMDB, National Eye Institute, Rockville, Maryland
    Centre for Brain Repair and Dept of Ophthalmology, University of Cambridge, Cambridge, United Kingdom
  • N. D. Bull
    Centre for Brain Repair and Dept of Ophthalmology, University of Cambridge, Cambridge, United Kingdom
  • S. I. Tomarev
    SMMG, LMDB, National Eye Institute, Rockville, Maryland
  • K. R. Martin
    Centre for Brain Repair and Dept of Ophthalmology, University of Cambridge, Cambridge, United Kingdom
  • Footnotes
    Commercial Relationships  T.V. Johnson, None; N.D. Bull, None; S.I. Tomarev, None; K.R. Martin, None.
  • Footnotes
    Support  GSK Clinician Scientist Fellowship (KRM); OxCam Scholarship and Gates Trust (TVJ); Fight for Sight (NDB); NEI Intramural Research Program (SIT) ; Cambridge University Hospitals NHS Foundation Trust;
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 2518. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. V. Johnson, N. D. Bull, S. I. Tomarev, K. R. Martin; Mesenchymal Stem Cell Transplantation Confers Neuroprotection in Experimental Glaucoma. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2518.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Glaucoma is characterized by progressive retinal ganglion cell (RGC) death and optic nerve degeneration. Retrograde neurotrophic factor transport blockade has been implicated in glaucomatous pathophysiology. Stem cell transplantation ameliorates some neurodegenerative conditions, apparently by neurotrophin secretion. This study was conducted to evaluate bone marrow-derived mesenchymal stem cell (MSC) transplantation as a novel neuroprotective glaucoma therapy.

Methods: : MSCs were isolated from adult transgenic rats with ubiquitous green fluorescent protein expression. In vitro, organotypic retinal explants were co-cultured with or without 3x103 MSCs for one week. RGC survival was assessed by immunohistochemistry. In vivo, live or dead MSCs were syngeneically transplanted intravitreally (3x104 cells) one week before, or intravenously (5x106 cells) on the day of, intraocular pressure (IOP) elevation by trabecular meshwork laser photocoagulation. Four weeks later, ocular MSC localization and integration were determined by immunohistochemistry. Optic nerve damage was assessed by axon quantification within optic nerve cross-sections.

Results: : In vitro,

Conclusions: : MSCs were strongly neuroprotective when cultured with retinal tissue in vitro and when transplanted locally but not systemically in a rat glaucoma model in vivo. Autologous intravitreal MSC transplantation should be considered as a potential neuroprotective therapy for glaucoma.

Keywords: neuroprotection • optic nerve • transplantation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×